Eye Diseases clinical trials at UCSF
2 in progress, 1 open to eligible people
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Advanced Vision Loss (Sirius)
open to eligible people ages 12 years and up
The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with advanced vision loss.
San Francisco, California and other locations
Rate of Progression in EYS Related Retinal Degeneration
Sorry, in progress, not accepting new patients
The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with EYS mutations in order to accelerate the development of outcome measures for clinical trials.
San Francisco, California and other locations
Our lead scientists for Eye Diseases research studies include Jacque Duncan, MD.
Last updated: